Douglas K. Pleskow

Beth Israel Deaconess Medical Center, Deaconess Hospital

Papers

Total Citations

242

H-Index

About

Dr. Douglas K. Pleskow is a leading figure in the treatment of gastrointestinal malignancies, with a particular focus on pancreatic and gastric cancers. His most impactful contribution is the landmark 2010 study on stereotactic body radiotherapy combined with gemcitabine for locally advanced pancreatic cancer, which has garnered 232 citations and helped establish a new paradigm for non-surgical management of this challenging disease. Dr. Pleskow has also advanced the field of radiosurgery for pancreatic cancer, demonstrating early innovation in fractionated approaches. More recently, he has turned his attention to gastric cancer, evaluating the treatment burden of robotic gastrectomy following neoadjuvant chemotherapy in a Western cohort. His 2021 work provides critical insights into perioperative outcomes, including narcotic consumption, oncologic efficacy, and resource utilization, while employing sophisticated statistical methods like CUSUM analysis to define learning curves. Through these contributions, Dr. Pleskow has shaped both the radiotherapeutic and surgical management of upper gastrointestinal cancers, with his work cited over 240 times across his most influential publications.